Jack Khouri (@khouri_jack) header
Jack Khouri (@khouri_jack) profile picture

Hematology/Oncology @CleClinicMD | Associate Prof @CWRUSOM #mmsm

Cleveland, OH
Joined May 2018
Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)Photo by Jack Khouri (@khouri_jack)
A major update from ASTCT! New consensus grading criteria refine CRS and ICANS assessments and address emerging toxicities following immune effector cell therapy, supporting standardized toxicity evaluation across clinical trials and practice. ow.ly/Wsig5103RX0
3
53
1
111
6,908
Bone marrow examination not universally necessary in otherwise typical chronic-phase #CML, see study in @AjHematology from @MayoClinic showing 100% cytogenetic concordance with peripheral blood karyotyping at diagnosis. #Hematology @MayoCancerCare onlinelibrary.wiley.com/doi/…
1
23
1
85
4,597
This critical review examines tools for predicting #CART toxicities, highlighting EASIX for severe CRS and ICANS and CAR-HEMATOTOX for prolonged cytopenia. Integrating clinical scores, CAR-T kinetics and imaging biomarkers may improve risk stratification. astctjournal.org/article/S26…
1
14
37
2,890
Jack Khouri retweeted
ASH has established new reference ranges for individuals with Duffy-null status, helping clinicians interpret blood counts more accurately and reduce unnecessary testing and treatment interruptions. ow.ly/b3Zm5104hvh
2
12
3
25
4,043
EPCORE DLBCL-2 Wow 😮 A lot of benefit—and a lot of $$$. HR 0.49 is enormous: a 51% reduction in progression or death with epcoritamab + R-CHOP in frontline higher-risk DLBCL. This is not a marginal improvement and could redefine treatment. But epcoritamab alone may add approximately $250,000 per patient at current US list price. Now we need the curves: absolute PFS benefit, NNT, durability, OS, toxicity—and which biological subgroups benefit most. The signal is unquestionably impressive. The full dataset will tell us whether treating everyone is justified. #DLBCL #HemeTwitter
1
7
1
61
3,553
Ok, looks like Epco-R-CHOP is ready for primetime. HR 0.49 is impressive, and will probably be the new SoC. What we eagerly wait: 1. Toxicity data 2. How Glofi-Pola-R-CHP will perform in the ph3 trial 3. Molecular data Exciting times ahead!
1
3
1
44
5,314
With a plethora of options now for early relapsed (1-3 prior LoT) #Myeloma who are either naive or exposed/sensitive to anti-CD38-mAb (except CART-4 which had 25% CD38-refractory), how does the MRD-negative CR rates compare across regimens? While BsAbs/CAR T remains at the top, impressive performance of Iber-Dara-Dex considering ~50% Len-refractory and 90% IMiD-exposed population. Remains to be seen how this translates into PFS! #IMS26
10
1
25
3,080
Jack Khouri retweeted
In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. Full study results: nej.md/4ArvK6r Science behind the Study: Anito-cel for Multiple Myeloma nej.md/4hF5Gxj
3
52
5
115
35,320
If you are in Glasgow #IMS26 stopby 12-1 pm poster- Mezigdomide post ide-cel in RRMM. We demonstrate in likited number that mezigdomide is safe as time limited maintenance for 1 yr at 0.6 mg. imsannual2026.eventscribe.ne…
2
13
1
49
2,683
Jack Khouri retweeted
Now online @NatureComms, our manuscript describing why the myeloma CAR T cell cilta-cel is more effective than a very similar CAR, ide-cel. Led by the very talented Kevin Herrera and Sneha Mitra, and in collaboration with the Leslie Laboratory. @MSKCancerCenter @szusmani
5
25
4
82
17,185
Replying to @BU_Amyloidosis
The Other Renal Amyloids: It’s not ALL about AL Amyloid by @vsanchorawala Amyloidosis isn’t synonymous with AL. Renal differential ➡️ ATTR, AA, ALECT2, AFib, AApoAI, AApoAIV, AApoCII, ALys. Typing the precursor protein determines treatment, prognosis and genetic implications.
3
17
768
Fully agree, Vaishali. Proud of this collaboration
Replying to @vsanchorawala
These findings reinforce the important role of fat pad sampling as a first-line diagnostic test and highlight the complementary value of combining minimally invasive tissue approaches when evaluating suspected AL amyloidosis. @BU_Amyloidosis @ASH_hematology @BloodAdvances
1
4
897
Jack Khouri retweeted
Not all CHIP is created equal when it comes to CAR-T…TP53 mutant CHIP stands out: ➡️ more cytopenias, higher baseline CAR HEMATOTOX, reduced CAR expansion and inferior outcomes ➡️ distinct inflamm. proteomic signature Just out in 📄 in @LeukemiaJnl nature.com/articles/s41375-0…
1
14
35
3,262
Pancreatic cancer is notoriously hard to treat, but we are making progress. Recent @theNCI -funded work that sheds light on mechanisms behind #daraxonrasib resistance and could help clinicians choose treatment combos that outsmart pancreatic tumors. go.nih.gov/AcvCu95
5
29
1
113
6,637
Immunoglobulin D-Associated AL Amyloidosis: Clinical Features and Outcomes - Clinical Lymphoma, Myeloma and Leukemia clinical-lymphoma-myeloma-le… @BU_Amyloidosis
9
23
989
I am a strong supporter of human-relevant cancer models. New research, funded in part by @NIH, adds ~150 3D organoids across 10 cancer types to DepMap—preserving tumor biology that 2D lines miss and revealing drug targets that might never have been found. go.nih.gov/C2SNHoR
4
22
2
75
4,868
Another chapter of #downwithdex, this time for AL amyloidosis! By the book, dex 20-40 mg QW for 6 months in ANDROMEDA. No need for this in real life. No ∆ in efficacy; rise in CHF exacerbations and ⬆️ diuretics with prolonged dex. I do 4-8 weeks of 12-20 mg then stop.
#Myeloma Paper of the Day: Limited duration (≤3 months) of dexamethasone in newly diagnosed AL #amyloidosis (w/ daratumumab-based regimen) results in higher 6-month CR rates (66.7 vs 30.4%, p<0.001) and reduced toxicity, similar organ responses: pubmed.ncbi.nlm.nih.gov/4256…. #alsm
3
13
30
4,945
#Myeloma Paper of the Day: 1F10, a novel high-affinity lambda subtype-specific amyloid-binding antibody enhances phagocytosis of amyloid; demonstrates robust activity in AL amyloidoma mouse model, accelerating resolution of lambda amyloid fibrils: pubmed.ncbi.nlm.nih.gov/4252…. #alsm
7
2
27
1,867